Literature DB >> 5773660

Hepatic lipidosis associated with L-asparaginase treatment.

M A Gross, R J Speer, J M Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5773660     DOI： 10.3181/00379727-130-33644

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  4 in total

1.  Factors influencing L-asparaginase production by Erwinia aroideae.

Authors:  R E Peterson; A Ciegler
Journal:  Appl Microbiol       Date:  1972-03

2.  The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.

Authors:  Gabriel J Wilson; Piyawan Bunpo; Judy K Cundiff; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-03       Impact factor: 4.310

3.  GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.

Authors:  Gabriel J Wilson; Brittany A Lennox; Pengxiang She; Emily T Mirek; Rana J T Al Baghdadi; Michael E Fusakio; Joseph L Dixon; Gregory C Henderson; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-12-09       Impact factor: 4.310

Review 4.  Drug-induced liver disease.

Authors:  H J Zimmerman
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.